US2011150902A1PendingUtilityA1

Treating cancer

57
Individually held — no corporate assignee on recordPriority: Jul 3, 2008Filed: Dec 27, 2010Published: Jun 23, 2011
Est. expiryJul 3, 2028(~1.9 yrs left)· nominal 20-yr term from priority
Inventors:Svetomir N. Markovic
A61K 2039/876A61P 35/00A61K 2039/545A61K 31/675A61K 31/555A61K 31/4188A61K 31/337A61K 45/06A61K 31/56C07K 16/22C07K 16/30A61K 39/3955C07K 2317/76A61P 29/00A61K 51/1069A61K 39/39533A61K 39/001191A61K 39/001156A61K 39/00115A61K 39/001192
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This document relates to methods and materials involved in treating cancer (e.g., melanoma). For example, methods and materials involved in using an anti-chronic inflammation treatment (e.g., chemotherapy) in combination with a cancer treatment agent (e.g., a cancer vaccine) to treat cancer are provided.

Claims

exact text as granted — not AI-modified
1 . A method for treating a mammal having cancer, said method comprising:
 (a) administering to said mammal an anti-chronic inflammation treatment under conditions wherein the level of global chronic inflammation in said mammal is reduced, and   (b) administering to said mammal a cancer treatment agent under conditions wherein the presence of said cancer is reduced.   
     
     
         2 . The method of  claim 1 , wherein said mammal is a human. 
     
     
         3 . The method of  claim 1 , wherein said cancer is melanoma. 
     
     
         4 . The method of  claim 1 , wherein said cancer is stage IV melanoma. 
     
     
         5 . The method of  claim 1 , wherein said anti-chronic inflammation treatment comprises chemotherapy, radiation, an anti-IL-4 agent, an anti-IL-13 agent, or a steroid treatment. 
     
     
         6 . The method of  claim 1 , wherein said cancer treatment agent is a cancer vaccine. 
     
     
         7 . The method of  claim 1 , wherein said cancer vaccine is a MART-1, gp100, or survivin cancer vaccine. 
     
     
         8 . The method of  claim 1 , wherein the period of time between the last administration of said anti-chronic inflammation treatment and the first administration of said cancer treatment agent is between two weeks and six months. 
     
     
         9 . A method for treating a mammal having cancer, said method comprising:
 (a) administering to said mammal an anti-TGFβ antibody under conditions wherein the level of global chronic inflammation in said mammal is reduced, and   (b) administering to said mammal a cancer treatment agent under conditions wherein the presence of said cancer is reduced.   
     
     
         10 . The method of  claim 9 , wherein said mammal is a human. 
     
     
         11 . The method of  claim 9 , wherein said cancer is melanoma. 
     
     
         12 . The method of  claim 9 , wherein said cancer is stage IV melanoma. 
     
     
         13 . The method of  claim 9 , wherein said cancer treatment agent is a cancer vaccine. 
     
     
         14 . The method of  claim 9 , wherein said cancer vaccine is a MART-1, gp100, or survivin cancer vaccine. 
     
     
         15 . The method of  claim 9 , wherein the period of time between the last administration of said anti-TGFβ antibody and the first administration of said cancer treatment agent is between two weeks and six months.

Join the waitlist — get patent alerts

Track US2011150902A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.